HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance83% confidence

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Novartis.

Regulatory Analysis

Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.

Supporting Context

Therapeutic area
Oncology · Pediatric
Sub-indication
Ild

Related signal: Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment

Source

View source document

Related Signal

Open signal — Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.